317 related articles for article (PubMed ID: 28654894)
1. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
2. Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells.
Schüler-Toprak S; Moehle C; Skrzypczak M; Ortmann O; Treeck O
BMC Cancer; 2017 May; 17(1):319. PubMed ID: 28482871
[TBL] [Abstract][Full Text] [Related]
3. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
4. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.
Sareddy GR; Pratap UP; Venkata PP; Zhou M; Alejo S; Viswanadhapalli S; Tekmal RR; Brenner AJ; Vadlamudi RK
Stem Cells; 2021 May; 39(5):536-550. PubMed ID: 33470499
[TBL] [Abstract][Full Text] [Related]
5. Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells.
Chu S; Nishi Y; Yanase T; Nawata H; Fuller PJ
Mol Endocrinol; 2004 Aug; 18(8):1919-28. PubMed ID: 15155785
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.
He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
9. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
10. Ovarian actions of estrogen receptor-β: an update.
Drummond AE; Fuller PJ
Semin Reprod Med; 2012 Jan; 30(1):32-8. PubMed ID: 22271292
[TBL] [Abstract][Full Text] [Related]
11. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.
Xiaomeng F; Lei L; Jinghong A; Juan J; Qi Y; Dandan Y
Braz J Med Biol Res; 2020; 53(6):e8885. PubMed ID: 32401925
[TBL] [Abstract][Full Text] [Related]
12. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
[TBL] [Abstract][Full Text] [Related]
13. Cancer therapy using natural ligands that target estrogen receptor beta.
Sareddy GR; Vadlamudi RK
Chin J Nat Med; 2015 Nov; 13(11):801-807. PubMed ID: 26614454
[TBL] [Abstract][Full Text] [Related]
14. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation.
Yu CP; Ho JY; Huang YT; Cha TL; Sun GH; Yu DS; Chang FW; Chen SP; Hsu RJ
PLoS One; 2013; 8(2):e56667. PubMed ID: 23460808
[TBL] [Abstract][Full Text] [Related]
15. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.
Yun H; Xie J; Olumi AF; Ghosh R; Kumar AP
Oncotarget; 2015 May; 6(13):11600-13. PubMed ID: 25816367
[TBL] [Abstract][Full Text] [Related]
16. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5.
Nakajima Y; Akaogi K; Suzuki T; Osakabe A; Yamaguchi C; Sunahara N; Ishida J; Kako K; Ogawa S; Fujimura T; Homma Y; Fukamizu A; Murayama A; Kimura K; Inoue S; Yanagisawa J
Sci Signal; 2011 Apr; 4(168):ra22. PubMed ID: 21487105
[TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Use of Estrogen Receptor β Agonists in Prevention and Treatment of Endocrine Therapy Resistant Breast Cancers: Observations From Preclinical Models.
Ramasamy K; Samayoa C; Krishnegowda N; Tekmal RR
Prog Mol Biol Transl Sci; 2017; 151():177-194. PubMed ID: 29096893
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
[TBL] [Abstract][Full Text] [Related]
20. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
Yang G; Xiao X; Rosen DG; Cheng X; Wu X; Chang B; Liu G; Xue F; Mercado-Uribe I; Chiao P; Du X; Liu J
Clin Cancer Res; 2011 Apr; 17(8):2181-94. PubMed ID: 21339307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
